Cholestyramine‐Induced Hyperchloremic Metabolic Acidosis

Paul J. Scheel, Andrew Whelton, Kevin Rossiter, Alan Watson

Research output: Contribution to journalArticlepeer-review

Abstract

Cholestyramine is a nonabsorbable anion exchange resin that is used predominantly for the treatment of hypercholesterolemia in adults and the management of acute diarrhea in children. The authors report two cases of severe hyperchloremic nonanion gap metabolic acidosis associated with the use of cholestyramine therapy. The authors recommend that patients taking cholestyramine who have concomitant renal insufficiency or who are volume depleted or who are taking spironolactone be monitored carefully for the emergence of a hyperchloremic metabolic acidosis. 1992 American College of Clinical Pharmacology

Original languageEnglish (US)
Pages (from-to)536-538
Number of pages3
JournalThe Journal of Clinical Pharmacology
Volume32
Issue number6
DOIs
StatePublished - Jun 1992

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Cholestyramine‐Induced Hyperchloremic Metabolic Acidosis'. Together they form a unique fingerprint.

Cite this